Why "One-Size-Fits-All" Treatment Plans Rarely Work for Mental Health
In most areas of medicine, personalization has become the standard. Oncologists sequence tumor genomes to identify the specific mutations driving a cancer, then select therapies targeted to those mutations. Cardiologists adjust treatment based on individual cholesterol subtype profiles, genetic clotting factors, and specific plaque characteristics. Rheumatologists distinguish between autoimmune subtypes that look similar clinically but require different immunological interventions.
Mental health care has been slower to catch up.
The dominant approach in conventional psychiatry remains population-based: identify a diagnosis using standardized symptom criteria, apply the evidence-based first-line treatment for that diagnosis, adjust if the first treatment fails, try the second-line treatment, and so on. The treatment algorithm is the same for every patient with a given diagnosis.
This approach fails a lot of people. Understanding why — and what personalization actually looks like in mental health care — matters enormously.
The Illusion of the Diagnosis
A psychiatric diagnosis is a description. It tells you what symptoms a patient has, in sufficient quantity and duration to meet threshold criteria. It says nothing about why those symptoms exist.
“Major depressive disorder” is not a specific disease with a known, uniform pathophysiology. It is a clinical label applied to a collection of symptoms — depressed mood, loss of interest, sleep disruption, appetite changes, cognitive difficulties, fatigue — that can arise from many different underlying biological mechanisms.
Two patients with identical MDDdiagnoses may have:
- Patient A: Undermethylation, elevated copper, pyrrole disorder — their brain is depleted of the raw materials for serotonin and dopamine synthesis, and their catecholamine system is dysregulated by copper excess
- Patient B: Hypothyroidism with normal TSH but low free T3, gut dysbiosis, systemic inflammation — their brain is receiving insufficient thyroid hormone signal and is bathed in inflammatory cytokines that impair serotonin metabolism
- Patient C: Severe vitamin D deficiency, MTHFR variant with elevated homocysteine, poor omega-3 status — multiple nutritional deficits affecting neurotransmitter synthesis and neuroplasticity
- Patient D: Trauma-driven HPA axis dysregulation with chronic cortisol elevation that has suppressed hippocampal neurogenesis and impaired reward circuit function
All four meet DSM criteria for MDD. All four have meaningfully different biology. None of them is well served by the assumption that their condition is the same as the others.
Why the Same Medication Doesn't Work for Everyone
The selective serotonin reuptake inhibitor (SSRI) is the most commonly prescribed antidepressant worldwide. For patients whose depression involves serotonin signaling deficits, SSRIs provide varying degrees of benefit.
But here is the reality of SSRI response rates:
- Approximately 30–40% of patients with MDD achieve remission on their first SSRI trial
- Another 30–40% experience partial response — improvement but not remission
- 20–30% show no meaningful response
These statistics are not anomalies. They reflect the fact that a significant proportion of patients whose depression doesn’t involve the specific mechanism that SSRIs address — serotonin reuptake inhibition — will not respond adequately to that intervention.
For Patient A above (undermethylation/copper excess), SSRIs that further reduce neurotransmitter reuptake in an already high-reuptake system may make things worse.
For Patient B (thyroid/inflammation), an SSRI does nothing about the inadequate thyroid hormone signal or the inflammatory cytokines suppressing serotonin synthesis.
For Patient C (nutrient deficiencies), the medication is trying to work with a substrate that’s missing key building blocks.
For Patient D (HPA dysregulation), the cortisol-mediated hippocampal effects that drive their depression aren’t addressed by serotonin reuptake inhibition at all.
The failure of SSRIs for these patients isn’t evidence of treatment-resistant depression. It’s evidence of treatment mismatch — the wrong tool for the specific mechanism.
The Clinical Consequences of One-Size-Fits-All Thinking
- Prolonged suffering. When treatment is standardized rather than individualized, patients whose conditions don’t match the implicit assumptions of the standard treatment spend years cycling through medication trials without resolution. Every year of inadequate treatment is a year of unnecessary suffering.
- Escalating polypharmacy. When the first medication doesn’t work, the standard response is to try another, then augment, then add more. Patients accumulate medications in an attempt to achieve the response that the correctly targeted treatment would have provided.
- Erosion of hope. Patients who don’t respond to multiple medications and multiple therapists often begin to believe that they are particularly difficult cases, that their brains are fundamentally broken, or that improvement simply isn’t possible for them. This is demoralizing and often inaccurate. They haven’t failed treatment. Treatment has failed them.
- Nutrient depletion from medications. Each psychiatric medication added to a protocol has metabolic consequences, including nutrient depletion. The longer a patient cycles through multiple medications without resolution, the more likely they are to develop iatrogenic (medication-caused) biochemical disruptions that compound their original problem.
What Genuine Individualization Requires
True individualization of mental health care requires identifying which of the many possible mechanisms is actually driving a specific patient’s symptoms. This is not possible within a 15-minute appointment with a symptom checklist.
It requires:
- Biochemical assessment. Understanding the patient’s actual neurochemical environment — methylation status, mineral balance, pyrrole levels, inflammatory markers, gut function, hormonal profile, nutrient status — through comprehensive testing. This information distinguishes between the patients who will respond to SAMe vs. SSRIs, who need copper reduction vs. zinc supplementation, who need gut restoration vs. methylation support.
- Clinical pattern recognition. The ability to integrate lab findings with clinical history and symptom patterns to identify biochemical subtypes. The undermethylated patient has a recognizable clinical profile — specific cognitive patterns, family history patterns, medication response patterns — that, combined with lab confirmation, points clearly toward the right intervention. The same is true of the pyrrole disorder patient, the copper-toxic patient, the inflammatory-depression patient.
- Treatment matched to mechanism. Designing treatment based on what is actually driving the patient’s symptoms, rather than applying the standardized algorithm for the diagnostic label.
- Monitoring and adjustment. Following objective markers — labs — to confirm that the treatment is achieving the intended biochemical changes, and adjusting when it isn’t.
This is what individualized mental health care looks like. It is more work, more time, and more expensive than population-based protocol application. But for patients whose conditions don’t respond to population-based approaches, it is the only path to genuine resolution.
Personalized Medicine Is the Future — And the Present
The concept of precision medicine — treatment based on an individual’s specific genetic, biochemical, and environmental profile — is now widely recognized as the future direction of medicine. In oncology and cardiology, it is already the present.
Mental health is catching up. Pharmacogenomic testing (to predict medication response based on genetic variants) is now available and beginning to be used clinically. Research into biomarker-based psychiatric diagnosis and treatment selection is expanding rapidly. The recognition that psychiatric diagnoses are not homogeneous biological entities — that they describe symptom clusters arising from multiple different mechanisms — is now mainstream in research circles, even if clinical practice has been slow to follow.
Functional and orthomolecular medicine approaches that identify and address individual biochemical mechanisms are, in a real sense, the clinical application of precision medicine principles to psychiatry. They are ahead of mainstream practice — but not ahead of the science.
Your diagnosis tells you what you have. Bioindividual medicine asks why.
At MN Mensah Medical, we reject the one-size-fits-all model. Our comprehensive evaluation identifies the specific biological mechanisms driving your symptoms — and our treatment protocols are built around your unique biochemistry, not a population average.
Schedule a consultation to experience what genuinely personalized mental health care looks like.